First-Line HIV Treatment
The Latest
This Week in HIV Research: The Real-World Effects of COVID-19
Oct. 22, 2020: Impact of COVID-19 shutdowns on HIV viral suppression; unsuppressed HIV viral load despite no treatment failure; point-of-care rapid testing vs. lab testing; it's not about "what," it's about "when."
Immediate HIV Treatment Initiation With Integrase Inhibitors Leads to Large Drop in Secondary HIV Transmission Among MSM
Integrase inhibitors are known to be potent first-line therapy options. Recent research suggests their benefits extend to onward HIV prevention as well.
This Week in HIV Research: So Many Relative Risks
July 1, 2020: Quantifying bone fracture risks; real-world lipid effects of switching to TAF; pulmonary function impairment in MSM; immunomodulatory drugs and viral load blips.
Scientists Report Documented Sustained HIV Remission in a 4-Year-Old Child
Treating newborns with antiretroviral therapy in the hours after birth may help put HIV into remission.
Weight Gain and HIV Antiretrovirals: Lipodystrophy for the Integrase Era
In a busy year buzzing with the flight of potentially revolutionary new HIV medications, evidence of large weight increases accompanying dolutegravir and bictegravir has been a bombshell.
TANGO, the Most Relevant Two-Drug Antiretroviral Therapy Trial of the Year
Whether lamivudine/dolutegravir is sufficient to achieve and maintain viral suppression was last year's question. As we move to 2020, a new question could be asked: Are three-drug regimens still necessary?
This Week in HIV Research: If I Could Turn Back Ossein
Nov. 7, 2019: Zoledronic acid to prevent bone loss; bone benefits for older patients switching from TDF to TAF; periperhal artery disease among women; motor dysfunction and cognitive impairment.
Two-Drug HIV Regimen Works Well Except in People With Low CD4 Count, Study Finds
The combination of dolutegravir and lamivudine is effective for treatment-naive patients regardless of age, gender, or race, according to a new subgroup analysis of the GEMINI clinical studies.
This Week in HIV Research: When STIs Flock Together
July 18, 2019: Anal neoplasia risk amidst comorbid HPV and chlamydia; predictive modeling for PrEP outreach; long-term benefits of hepatitis C cure in coinfection; first-line therapy with dolutegravir/lamivudine.
After Pilot, Whitman-Walker Health Establishes Same-Day HIV Treatment Start Program
"We're very much putting the patient in the driver's seat," said Heather Alt, deputy director of nursing with Whitman-Walker. "If folks didn't feel ready, we would not push them to start."